(Q40960931)

25 September 2017

1 reference

title

Targeting fungi: a challenge (English)

1 reference

25 September 2017

F Meunier

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

99

1 reference

25 September 2017

issue

6A

1 reference

25 September 2017

page(s)

60S-67S

1 reference

Risk factors for nosocomial candidemia: a case-control study in adults without leukemia

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Candida: an increasingly important pathogen in the nursery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Nosocomial fungemia in a large community teaching hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Impact of the changing epidemiology of fungal infections in the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Fungal infections in cancer patients: an international autopsy survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Infection with Fusarium species in two children with neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Candidemia in immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Invasive aspergillosis. Progress in early diagnosis and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Epidemiological typing methods for mycoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Detection of amphotericin B-resistant Candida isolates in a broth-based system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Resistance of Candida species to fluconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Incidence of polyene-resistant yeasts recovered from clinical specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Correlation between in vitro and in vivo activity of antifungal agents against Candida species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Invasive candida infections--evolution of a fungal pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

7 January 2021

Management of candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Clinical use of liposomal and lipid-complexed amphotericin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Colony-stimulating factors and neutropenia: intersection of data and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Antifungal prophylaxis: to prevent or not

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

The prophylactic use of low-dose amphotericin B in bone marrow transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Granulocyte growth factors: achieving a consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

7 January 2021

inferred from DOI database lookup

Diagnosis of systemic candidiasis by an enzyme-linked dot immunobinding assay for a circulating immunodominant 47-kilodalton antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

7 January 2021

inferred from DOI database lookup

Single-source outbreak of Candida tropicalis complicating coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980291-5

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0002-9343(99)80291-5

1 reference

release_igdd7gxzivhfxbx6cz75mkyqom

25 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/igdd7gxzivhfxbx6cz75mkyqom

24 November 2022

mapped directly with Wikidata item

1 reference